Pediatr Res 1984;18(7):679-81
There is limited evidence in the literature on the use of pro-motility agents to decrease the risk of pulmonary aspiration in patients on GLP1 agonists undergoing medical procedures
Fifty of the 173 users discontinued the agents before the 1-year study period was up, most often for gastrointestinal symptoms and "insurance issues." Limitations to the study included its single-center, retrospective design and small sample size
All such applications are strictly for non-human, in vitro or in vivo research to advance fundamental scientific understanding
All products must be handled only by licensed, qualified, and properly trained research professionals
Bridge program NovoCare self-pay program: approximately $199 per month for starting doses (0.25/0.5 mg, first two fills through December 31, 2026), then approximately $349 per month for standard doses